KRAS ACTIVATING MUTATION
Clinical trials for KRAS ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for KRAS ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to outsmart tough lung cancer
Disease control OngoingThis study is testing whether combining two or three different drugs is safe and effective for treating advanced non-small cell lung cancer with a specific genetic mutation called KRAS G12C. It is for adults whose cancer has progressed after prior treatments, including some who h…
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New Four-Drug attack on deadly pancreatic cancer enters human testing
Disease control OngoingThis study is testing a new combination of four drugs for people with metastatic pancreatic cancer who have not yet received any treatment. The main goals are to find the safest and most effective dose of the new drug pair (avutometinib and defactinib) when added to two standard …
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC